Mesane kanserinde klinik ve patolojik özelliklerin önemi ve hastalık seyrine etkisi

Amaç: Mesane kanseri (MK), üriner sistemin en sık görülen malignitesidir ve görülme sıklığı bölgelere göre değişmektedir. Mesane kanseri erkeklerde kadınlardan daha yaygındır. Tümör evresi ve derecesi, MK'nin en önemli prognostik faktörleridir. Bu çalışmamızda mesane kanserinin klinik ve patolojik özelliklerini belirlemeyi, ayrıca bu özelliklerin prognostik değerleri ve hasta sağkalımı üzerine etkilerini incelemeyi amaçladık. Yöntemler: Çalışmaya mesane kanseri tanısı konan hastalar (kas tutulumu olmayan veya kas tutulumu olan) dahil edildi. Mesane içi tedavi tipi, tümör çapı, patolojik derece, tümörün oluştuğu bölge ve tümör evresi değişken olarak kaydedildi. Hastaların sağkalım oranları; tümör çapı, tümörün histopatolojik derecesi ve hastalığın evresi gibi çeşitli parametrelerle ilişkilendirildi. Bulgular: Toplam 124 hastanın 23'ü (%18,5) kadın, 101'i (%81,5) erkek, tüm hastaların ortalama yaşı 64 idi (21-92). Erken evrede %36 (41) hasta (evre 0 veya evre insitu), evre 1'de %50,9 (58) hasta, evre 2'de %7 (8), evre 3'te %4,4 (5) hasta ve evre 4’te %1,8'i (2) hasta saptandı. Evreler arası sağkalım oranları arasındaki fark istatistiksel olarak anlamlı idi (p

The importance of clinical and pathological features in bladder cancer and its effects on disease course

Objective: Bladder cancer (BC) is the most common malignancy of the urinary system and the incidence of BC variesregionally. Bladder cancer is more common in men than in women. Tumor stage and grade are the most importantprognostic factors of BC. We aimed to describe the patterns of BC presentation and to examine the differences in thedistribution of prognostic factors by gender, age, tumor size, and involvement region.Method: The patients diagnosed with BC (non-muscle invasive or muscle-invasive BC) were included. Intravesicaltreatment, tumor diameter, pathological grade, tumor involved area and tumor stage were recorded as variables. Thesurvival rates of the patients were calculated for diverse clinical and pathological findings.Results:In a total of 124 patients, 23 (18.5%) of patients were female and 101(81.5%) of patients were male, themedian age of all patients was 64 (IQR: 21-92). There were 36 % (41) patients in early-stage (stage 0 or stage insitu),50.9 % (58) patients in stage 1, 7% (8) patients in stage 2, 4.4 %(5) patients in stage 3 and 1.8% (2) patients were instage 4. There were significantly different OS rates of patients with BC in different stages (p2.5cm (group 2). There was asignificant difference between the overall survival rates of group 1 and group 2(p=0.02). There were 55 patients withlow-grade BC and 38 of patients with high-grade BC, and the difference between their survival rates was statisticallysignificant (p=0.001).Conclusions: Tumor stage, tumor diameter, and grade were demonstrated and confirmed as the crucial prognosticfactors of bladder cancer. Additionally, lateral walls of bladder constitute the most commonly involved area, but theirroles in the disease course still remain unclear.

PDF

___

1. Ploeg M, Aben KK, KiemeneyLA.The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289-293.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
3. Jankovic S, Radosavljevic V. Risk factors for bladder cancer. Tumori. 2007; 93:4-12.
4. Hinotsu S, Akaza H, Miki T, et al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol. 2009;16:64-69.
5. Mungan NA, Kiemeney LA, van Dijck JA, van der Poel HG, Witjes JA. Gender differences in stage distribution of bladder cancer. Urology. 2000;55:368-71.
6. Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006;107:2173-9.
7. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-77.
8. Cambier S, Sylvester RJ, Collette L, et al: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol. 2016;69:60-9.
9. Kirkali Z, Chan T, Manoharan M, et al: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4-34.
10. Linn JF, Sesterhenn I, Mostofi FK, Schoenberg M. The molecular characteristics of bladder cancer in young patients. J Urol. 1998;159:1493-6.
11. Jancke G, Rosell J, Jahnson S. Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder. Scand J UrolNephrol. 2011;45:388-92.
12. Amin MB, McKenney JK, Paner GP, et al: ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. Eur Urol. 2013;63:16-35.
13. Kim W, Song C, Park S,et al. Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor. J Endourol. 2012;26:1059-64.
14. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA: a cancer journal for clinicians. 2017;67:93-9.
15. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64:639-53.
16. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA: a cancer journal for clinicians. 2016;66:271-89.
17. Ajili F, Darouiche A, Chebil M, Boubaker S. The efficiency of the EORTC scoring system for the prediction of recurrence and progression of nonmuscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy. UltrastructPathol. 2013;37:249-53.
18. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Busch C, Johansson SL. Recurrence and progression in low grade papillary urothelial tumors. J Urol. 1999;162:702-7.
19. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130:1083-6.
20. Lebret T, Bohin D, Kassardjian Z, et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol. 2000;163:63-7.
21. Hubsher CP, Jansen R, Riggs DR, Jackson BJ, Zaslau S. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Can J Urol. 2012; 19:6480-4.
22. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964-70.
23. Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur Urol. 2000;37:9- 15.
24. May M, Brookman-Amissah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol. 2010;57:850-8.
25. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124-9.
26. Xiao GQ, Rashid H. Bladder Neck Urothelial Carcinoma: A Urinary Bladder Subsite Carcinoma With Distinct Clinicopathology. Int J SurgPathol. 2015; 23:517-23.
27. Stephenson WT, Holmes FF, Noble MJ, Gerald KB. Analysis of bladder carcinoma by subsite. Cystoscopic location may have prognostic value. Cancer. 1990;66:1630-5.
28. Wedel SA, Jones J, Tsaur I, et al. Association of intravesical tumor location with metastases to the pelvic lymph nodes in transitional cell cancer of the bladder. Am J Med Sci. 2010;339:341-4.
29. Vukomanovic I, Colovic V, Soldatovic I, Hadzi-Djokic J. Prognostic significance of tumor location in high-grade non-muscle-invasive bladder cancer. Med Oncol. 2012;29:1916-20.
30. Mulders PF, Hoekstra WJ, Heybroek RP, et al. Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group. Eur J Cancer. 1994;30A:914-7.